Get startedLog in
    Picture of HLS Therapeutics logo

    HLS — HLS Therapeutics Cashflow Statement

    0.000.00%
    ca flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for HLS Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-15.3-13.1-23.6-27.5-19.7
    Depreciation
    Deferred Taxes
    Non-Cash Items1.640.1233.929.532.93
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-7.67-1.982.082.55-1.8
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Payable / Accrued Expenses
    Change in Taxes Payable
    Net Change in Other Assets & Liabilities
    Cash from Operating Activities9.3416.416.915.88
    Capital Expenditures-32.6-0.69-0.148-0.189-0.015
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-12.1-3.82-10011.8
    Acquisition of Business
    Other Investing Cash Flow
    Cash from Investing Activities-44.7-4.51-10.1-0.18911.7
    Financing Cash Flow Items-0.6580-0.639-1.36-1.19
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities9.56-11.4-6.86-14.6-23.4
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-26.50.567-0.4561.23-4.5